Levetiracetam Treatment of Tardive Dyskinesia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00291213
Recruitment Status : Completed
First Posted : February 13, 2006
Last Update Posted : June 6, 2014
UCB Pharma
Information provided by (Responsible Party):
Yale University

Brief Summary:
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.

Condition or disease Intervention/treatment Phase
Tardive Dyskinesia Drug: levetiracetam Drug: placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Actual Primary Completion Date : April 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Levetiracetram Administration Drug: levetiracetam
Placebo Comparator: Placebo Drug: placebo

Primary Outcome Measures :
  1. Abnormal Involuntary Movement Scale (AIMS) Total Score [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: meet Glazer Morgenstern criteria for TD -

Exclusion Criteria: none

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00291213

United States, Connecticut
Connecticut Mental Health Center
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
UCB Pharma
Principal Investigator: Scott W Woods, MD Yale School of Medicine

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Yale University Identifier: NCT00291213     History of Changes
Other Study ID Numbers: YaleHIC26585
First Posted: February 13, 2006    Key Record Dates
Last Update Posted: June 6, 2014
Last Verified: June 2014

Additional relevant MeSH terms:
Tardive Dyskinesia
Dyskinesia, Drug-Induced
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs